Select Page

EVQLV

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

read more
EVQLV Joins Endless Frontier Labs Incubator

EVQLV Joins Endless Frontier Labs Incubator

NEW YORK, September 21, 2020 -- EVQLV has been invited to join the Life Science Track of the prestigious Endless Frontier Labs (EFL) incubator. The nine-month program runs each year from October through May. The program provides: Guidance from industry executives to...

read more
Large Pharma’s Embrace of Artificial Intelligence

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

read more
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

read more